Page 3 - Priority Review News Today

Zanidatamab is a HER2-targeted bispecific antibody that can simultaneously bind 2 non-overlapping epitopes of the HER2 receptor.

New trial confirmed safety and efficacy of a subcutaneous add-on therapy for uncontrolled COPD.

(RTTNews) - Sanofi - Aventis Groupe said that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics Li...

The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for the investigational use of Sarclisa in combination with bortezomib,...

Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma FDA Priority Review granted based on positive results from IMROZ phase

/PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd., announced today that it has received preliminary analysis results from...

Media contacts: Investor contact: ...

DREAMM-8 results for Blenrep in multiple myeloma featured in a late-breaking presentation and ASCOs Press Programme Updated results from a supported...

VBI Vaccines Inc. , a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the...

The open-label phase 3 ASSURE study evaluated the long-term safety and efficacy of seladelpar in PBC patients who have already participated in other PBC trials of seladelpar.